Role of Cytokines in Acute Ischemic Stroke Patients: Preliminary Analysis of a Prospective Database (5521)

Objective: To find the role of various cytokines as blood biomarkers in Acute Ischemic Stroke patients Background: Acute ischemic stroke (AIS) is a leading cause of disability with alteplase as the only acute pharmacological treatment approved to date. Various modalities of management and diagnosis are being evaluated. The role of various cytokines is of particular interest. There is limited data on the role of various cytokines such as IL1, IL-6, IL-23, IL-37, MPO and MMP-9 in patients with acute ischemic stroke. This current study is a preliminary analysis of a large prospective study. Design/Methods: This prospective study was approved by the institutional IRB. Patients presenting to an academic tertiary hospital with the diagnosis of AIS were included. All the patients with prior history of stroke, autoimmune diseases, and neurodegenerative diseases were excluded. Patients were categorized into two grouped: AIS group and Control group. The trends in plasma levels of above mentioned cytokines were measured by enzyme-linked immunosorbent assay (ELISA). Results: This is a preliminary data from a subset of the anticipated larger cohort. Fifty five consenting patients (45 cases and 5 controls) were analyzed in the first phase. There were 23 females in AIS and 6 females in control groups. Caucasian and Hispanics were primarily the predominant ethnicity in both groups. The study showed positive trend of Plasma IL-33, IL-37, and MPO levels between the two groups but the difference was not statistically significant. Conclusions: This preliminary data showed a trend of elevated plasma IL-33, IL-37 and MPO levels in AIS patients as compared to control subjects. These are early observations from an anticipated a large-scale prospective study “CRISP” trial registered with the ClinicalTrials.gov (Identifier: NCT03297827) to determine the role of various cytokines, in modulating post-stroke inflammation. Disclosure: Dr. Suriya has nothing to disclose. Dr. Farooqui has nothing to disclose. Dr. Ikram has nothing to disclose. Dr. Qaryouti has nothing to disclose. Dr. Quadri has nothing to disclose. Dr. Ortega Gutierrez has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Medtronic and Stryker Neurovascular. Dr. Qeadan has nothing to disclose. Dr. Zafar has nothing to disclose.